Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 75 Publications

13 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NYi2O49wS3m2b4TvfIlkKEG|c3H5 NVjVe2xXPDhiaB?= MU\EUXNQ NHT3WZNEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRiY3;lfJBz\XO|aX7nJGVOVDRid3n0bEBKSzVyIH;mJFAvPjJizszN MlHYNlE2PzJ3OEm=
BAF3 M1nwSmN6fG:2b4jpZ{BCe3OjeR?= MVW0PEBp NVPGXYdUTE2VTx?= NV;veWN6S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFHMT{BNOTF7Nl2gcZV1[W62IHPv[ZhxemW|c3nu[{BGVUx2IIfpeIghUUN3MDDv[kAzNjJizszN NGjjfJczOTV5MkW4PS=>
BAF3 M37lOWN6fG:2b4jpZ{BCe3OjeR?= M4ToVVQ5KGh? NVP6N3JETE2VTx?= MlTWR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKHerdHigTWM2OCCxZjCwMlI5KM7:TR?= M3G1RVIyPTd{NUi5
Kelly NWm1fFlPS3m2b4TvfIlkKEG|c3H5 MWHEUXNQ M1\3NWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPDJizszN M1zkZVIyPTd{NUi5
SH-SY5Y NYjQR49[S3m2b4TvfIlkKEG|c3H5 NYPtXI81TE2VTx?= NYiyU|dpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0hvU2m1XUBk\WyuczDlfJBz\XO|aX7nJGFNUyCIMUG3OGwhdXW2YX70JJdqfGhiSVO1NEBw\iByLkWzJO69VQ>? MYKyNVU4OjV6OR?=
SMS-KCN MoOyR5l1d3SxeHnjJGF{e2G7 NHjD[GFFVVOR NUTBfmFCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW02VLVvDUkBk\WyuczDlfJBz\XO|aX7nJGFNUyCUMUK3OXEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkmxJO69VQ>? MkDGNlE2PzJ3OEm=
BAF3 MmX2R5l1d3SxeHnjJGF{e2G7 NGnXO5k1QCCq MX\EUXNQ Mny1R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3BUGshf2m2aDDJR|UxKG:oIECuNVkh|ryP M3y3WFIyPTd{NUi5
3T3 M{XIVWZ2dmO2aX;uJGF{e2G7 NVTJOI57OSCq NXXIZo5ITE2VTx?= M1PITWlvcGmkaYTpc44hd2ZiUl;OJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? MX2yNVgyOjRzNB?=
3T3-E NYPkeFE5TnWwY4Tpc44hSXO|YYm= MYWxJIg> NEizTmJFVVOR MX\Jcohq[mm2aX;uJI9nKFSLRUKgZZN{\XO|ZXSg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvPDR6IN88US=> M4TOUFIyQDF{NEG0
A549 MXLLbY5ie2ViQYPzZZk> MV:xJIg> M1P0UGROW09? NGrMPG5KdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IHOtUWVVKGurbnHz[UBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJT0ZvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByODFOwG0> NH3JNXozOThzMkSxOC=>
BAF3-BCL NVvIZ4JHTnWwY4Tpc44hSXO|YYm= NFiwOlMyKGh? MVXEUXNQ NFvmZ2lKdmirYnn0bY9vKG:oIFHCUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMT6xOVkh|ryP NHvococzOThzMkSxOC=>
HEK293 MVzGeY5kfGmxbjDBd5NigQ>? M2ryT|EhcA>? M4DLU2ROW09? NHfVbFNKdmirYnn0bY9vKG:oIFHYUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6yPVQh|ryP Mmr5NlE5OTJ2MUS=
HEK293 MXrGeY5kfGmxbjDBd5NigQ>? M2\iVVEhcA>? M1n3RmROW09? MX\Jcohq[mm2aX;uJI9nKEmUIHHzd4V{e2WmIHHzJIdzd3e2aDDmZYN1d3JvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAzNjh6NzFOwG0> M2L0eVIyQDF{NEG0
Jurkat MoL0SpVv[3Srb36gRZN{[Xl? NIrqRYwyKGh? MVjEUXNQ NILOVYdKdmirYnn0bY9vKG:oIFzDT{Bie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj63OFEh|ryP MmT5NlE5OTJ2MUS=
KARPAS299 NYe0WWF3U2mwYYPlJGF{e2G7 M4DnWlEhcA>? NGTaXXZFVVOR MoLkTY5pcWKrdHnvckBw\iCDTFugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO NUfsRmh{OjF6MUK0NVQ>
PAE M3f4cWZ2dmO2aX;uJGF{e2G7 NGfjSGsyKGh? NF;2XXFFVVOR NV33ZmxKUW6qaXLpeIlwdiCxZjDUVmtDKGG|c3Xzd4VlKGG|IHfyc5d1cCCoYXP0c5IucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlM6QSEQvF2= MnHBNlE5OTJ2MUS=
BAF3 MnjXSpVv[3Srb36gRZN{[Xl? NIC2[lgzNTNiZB?= MX3EUXNQ NVvEUlY3UW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgbY5{fWyrbjDy[YNmeHSxcjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDFwNkSzJO69VQ>? M3fyNFI{PzR{MkWy
KARPAS299 M4\LcGN6fG:2b4jpZ{BCe3OjeR?= NIGxVnEzNTNiZB?= NHXEeIxFVVOR MXLJR|UxRTBwME[0NkDPxE1? M3vtN|I{PzR{MkWy
EBC1 NGL2cJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy0NZk4OiCq MUnEUXNQ MnXQTWM2OD1yLkCyN{DPxE1? M{H2flI{QTl|M{K4
HCT116 NVzIZ4pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrqN|N1PzJiaB?= MX7EUXNQ NFTUWllKSzVyPUG0MlgzKM7:TR?= NV;BOGt4OjN7OUOzNlg>
MCF7 NVL3N3F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPIO|IhcA>? NIr2[2FFVVOR NYixXlF6UUN3ME25MlU5KM7:TR?= NYTWb2JHOjN7OUOzNlg>
MDA-MB-231 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Dae|czKGh? M2jBeWROW09? NHLReVZKSzVyPUGwMlgh|ryP NE[xe2ozOzl7M{OyPC=>
MKN45 NV[3emcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnUO|IhcA>? NYnsPJFjTE2VTx?= MY\JR|UxRTBwMEGzJO69VQ>? NYDqNZg4OjN7OUOzNlg>
NCI-H441 NEfjRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;5O|IhcA>? M3ToNWROW09? M4rFeWlEPTB;MUeuNlUh|ryP M2PQUFI{QTl|M{K4
NCI-H661 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknSO|IhcA>? MYjEUXNQ MYjJR|UxRTFzLkS3JO69VQ>? NUPHZpFoOjN7OUOzNlg>
SK-MEL-28 NWD2b2VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLCdWw4OiCq NUK5[4U{TE2VTx?= MkPUTWM2OD1zMD65O{DPxE1? M{jubVI{QTl|M{K4
SKOV3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO3TlR3PzJiaB?= MULEUXNQ MonXTWM2OD1zMj64OUDPxE1? MonVNlM6QTN|Mki=
SNU5 MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH0e|E4OiCq MmK4SG1UVw>? MUTJR|UxRTBwMEG2JO69VQ>? Mkj4NlM6QTN|Mki=
NCI-H2228 NEjXVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHaOXliPzJiaB?= MWTEUXNQ NEH2NIFKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5zMUig{txO NGeyXI0zPDR|MkmwPS=>
NCI-H3122 NFzXSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[xXFczKGh? M3jtUWROW09? NELjSllKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5zMEig{txO NX3wWGVDOjR2M{K5NFk>
NCI-H3122 M{PNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqyN3JZPzJiaB?= NYDyVopnTE2VTx?= NEThbldKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BIOTJ4OVGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjZ{MzFOwG0> NXLkUWtJOjR2M{K5NFk>
NCI-H3122 M{LsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr1bJo4OiCq NGjpcJhFVVOR M{fiVWlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIHnuJIh2dWGwIF7DTU1JOzF{MjDj[YxteyCqYYLic5JqdmdiQVzLJGwyOTl4TTDteZRidnRid3n0bEBKSzVyIH;mJFAvQDN6IN88US=> M4DWeVI1PDN{OUC5
NIH-3T3 MUjLbY5ie2ViQYPzZZk> NHvXZm8yKGh? MVPEUXNQ NHzzW4RKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCHTVy0MYZ2e2WmIFHMT{BmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0[YQhSUyNIHzleoVtKHerdHigTWM2OCCxZjCwMlA5KM7:TR?= MlTSNlQ1OzJ7MEm=
NIH-3T3 MYDLbY5ie2ViQYPzZZk> NFHB[YkyKGh? MkPHSG1UVw>? M3jndWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS|EzPjmDIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNkC1JO69VQ>? Mn;ZNlQ1OzJ7MEm=
NIH-3T3 M2TQT2tqdmG|ZTDBd5NigQ>? MYixJIg> M3fadGROW09? M4mwUGlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugV|EzOD[\IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNkK2JO69VQ>? MljmNlQ1OzJ7MEm=
NIH-3T3 M2WzeWtqdmG|ZTDBd5NigQ>? M1PhTlEhcA>? NW\TTIp1TE2VTx?= NFXnSHVKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLki0N{DPxE1? NHHnXmQzPDR|MkmwPS=>
NIH-3T3 MknQT4lv[XOnIFHzd4F6 NWjORW54OSCq MoXtSG1UVw>? NXy2TY9WUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF3MmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6wNlYh|ryP NYnoclRHOjR2M{K5NFk>
BAF3 NVzXZYNkTnWwY4Tpc44hSXO|YYm= M1TlSFczKGh? Mk\uSG1UVw>? MXrJcohq[mm2aX;uJI9nKE6STT;BUGshfHKjboPm[YN1\WRiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNE4xPTFizszN M1n1OVI1PDZ6NkOy
BAF3 MmTSR5l1d3SxeHnjJGF{e2G7 MV23NkBp MXLEUXNQ MlH2TWM2OD1yLkm4JO69VQ>? NH62NGwzPDR4OE[zNi=>
NIH-3T3 NGLqVFBMcW6jc3WgRZN{[Xl? M2nGfVEhcA>? Mn3HTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDGNVE4PExibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC5zNkWg{txO NFnacnQzPDhzOUGxOi=>
NIH-3T3 NU\KWpNYU2mwYYPlJGF{e2G7 NV32SGI5OSCq MVLJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjR5ODFOwG0> MUKyOFgyQTFzNh?=
NIH-3T3 M3\CXGtqdmG|ZTDBd5NigQ>? NIn5bYEyKGh? MVzJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlAzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjF2ODFOwG0> MmPZNlQ5OTlzMU[=
NIH-3T3 NUe3eIVmU2mwYYPlJGF{e2G7 M3OwUFEhcA>? NYTkbmhVUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKHerdHigTWM2OCCxZjCzMlA{QSEQvF2= M1K2PFI1QDF7MUG2
KARPAS299 MU\LbY5ie2ViQYPzZZk> Ml36PVAhdWmw M1SxWWROW09? NWT1RXNiUW6qaXLpeIlwdiCxZjDOVG0u\nW|ZXSgRWxMKHCqb4PwbI9zgWyjdHnvckBmgHC{ZYPz[YQhf2m2aDDJR|UxKG:oIECuNVEh|ryP MkThNlQ6ODB5NUC=
MKN 45 NYXnT25QU2mwYYPlJGF{e2G7 M1rDNFEhcA>? MXzEUXNQ NGLkb3NKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNkDPxE1? NFS5fngzPDlyMEe1NC=>
A549 NEPUT2REgXSxdH;4bYMhSXO|YYm= M{mxdFQ5KGh? NGfGW5ZFVVOR M1zmSGlEPTBib3[gOE4xQDRizszN NIHEPFYzPDlyMEizNC=>
NCI-H1975 M3zrO2N6fG:2b4jpZ{BCe3OjeR?= NWjNN3d4PDhiaB?= M3HyU2ROW09? NIDmUVBKSzVyIH;mJFcvPTVzIN88US=> MoOzNlQ6ODB6M{C=
NCI-H1993 MojCR5l1d3SxeHnjJGF{e2G7 NHnKdnU1QCCq MnO3SG1UVw>? MUTJR|UxKG:oIECuNFYyKM7:TR?= M3HleFI1QTByOEOw
NCI-H1993 MoGzRZBwfG:|aYOgRZN{[Xl? MnvxNUDPxE1? MkjlNlQhcA>? NGrVN3JFVVOR NGfwWWZld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz NIXJT4MzPDlyMEizNC=>
NIH-3T3 Mnq2R5l1d3SxeHnjJGF{e2G7 NH3xRnM1QCCq MkS5SG1UVw>? NX;FXVNwUUN3MDDv[kAxNjN4NDFOwG0> NF\hPJQzPDlyMEizNC=>
EBC1 MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P0[FczKGh? Mn;PSG1UVw>? MXvJR|UxKG:oIECuNFA3QSEQvF2= NVX0d3VxOjR7MEC4N|E>
KARPAS299 M1izW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO4O|IhcA>? MlnaSG1UVw>? MX3JR|UxKG:oIECuNkDPxE1? NVvm[3g4OjR7MEC4N|E>
NB1 NFTCbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDZTGczUUN3ME25NU46QCCwTR?= NH:5NlJUSU6JRWK=
NCI-SNU-5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFyNT63OUBvVQ>? NITwVGxUSU6JRWK=
SR Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHoXJVtUUN3ME2xNlYvOzFibl2= NX\FN2Q6W0GQR1XS
SF539 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjyWlNNUUN3ME2yNFQvOjRibl2= NFf1XFVUSU6JRWK=
SU-DHL-1 MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDkTWM2OD1|M{[uPFIhdk1? MWDTRW5ITVJ?
SCC-3 MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTPbplbUUN3ME2zOVYvPzZibl2= MYfTRW5ITVJ?
DEL NFPPN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN4OT65JI5O MUjTRW5ITVJ?
CTV-1 NYjNeHJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWGwVnQzUUN3ME21PVYvPDhibl2= MnTxV2FPT0WU
EM-2 NEOxcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTZyMT6zOEBvVQ>? MXrTRW5ITVJ?
MHH-CALL-2 NVzmbYxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7GTWM2OD14OEKuOVchdk1? NILIPI5USU6JRWK=
KM12 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\ITWM2OD15ME[uPUBvVQ>? NUW1[WZOW0GQR1XS
KINGS-1 NXzDUGZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX72VoJEUUN3ME23OFkvPzVibl2= MWTTRW5ITVJ?
MEG-01 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTh3Nz62OkBvVQ>? NIjtR3JUSU6JRWK=
BV-173 NWrjd3A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwMEW5PVch|ryP NYDMeII6W0GQR1XS
LAMA-84 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG2UZkxUUN3ME2xMlM5Ojh{IN88US=> NWDJOZJXW0GQR1XS
KARPAS-299 NUDYSWU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HhT2lEPTB;MT60NFg3OSEQvF2= MXXTRW5ITVJ?
K-562 NGLJeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rUV2lEPTB;MT63NlI3QSEQvF2= MYrTRW5ITVJ?
SK-LMS-1 NUjXWYFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwN{[4Olch|ryP M{m0cXNCVkeHUh?=
MOLT-16 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe2bG9KSzVyPUGuPVU2PzVizszN MVvTRW5ITVJ?
CMK MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSzTWM2OD1zLkm2NVU6KM7:TR?= M2PnT3NCVkeHUh?=
ST486 MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHFSmV3UUN3ME2yMlQ{ODd|IN88US=> M{i5cXNCVkeHUh?=
CI-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPpUI5uUUN3ME2yMlQ6PjV7IN88US=> NV;LXHFqW0GQR1XS
KP-N-RT-BM-1 M1u3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTZNFlKSzVyPUKuO|AyOjJizszN NVztenRXW0GQR1XS
ALL-PO MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTNwMUiyNFch|ryP Mk\jV2FPT0WU
KS-1 M1vNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTLXnNNUUN3ME2zMlIyOjJ3IN88US=> M{[4NXNCVkeHUh?=
Becker NX\UXmNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTRwMkO5N{DPxE1? M{frWXNCVkeHUh?=
GDM-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDjNXU2UUN3ME20MlI1PjF5IN88US=> M{HCcHNCVkeHUh?=
BC-1 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\H[WlEPTB;ND60PVI4PyEQvF2= NVjGPFZ1W0GQR1XS
NB14 NWm4bYV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2yOVZWUUN3ME20Mlg{PTJ2IN88US=> NXyyN3NTW0GQR1XS
NOS-1 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT5TWM2OD13LkOzPFc1KM7:TR?= M1\sdXNCVkeHUh?=
MZ1-PC NHLhWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnYNHQ1UUN3ME21MlgzOTVzIN88US=> MXfTRW5ITVJ?
A498 NFKwV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXF[5VKSzVyPU[uNFg1PzNizszN M4X6O3NCVkeHUh?=
EW-16 M{H6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnKXWhKSzVyPU[uN|c4PzNizszN MoX1V2FPT0WU
NALM-6 NGDpd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv2W5Z4UUN3ME22MlY5Ozh5IN88US=> NIC4d4RUSU6JRWK=
EB-3 MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTdwMEeyN|Mh|ryP M3HwOXNCVkeHUh?=
697 NGSx[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PtVmlEPTB;OT6yOFMzQSEQvF2= NGS1cZpUSU6JRWK=
Ramos-2G6-4C10 M{XDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTlwNUm4OFIh|ryP MXfTRW5ITVJ?
KNS-81-FD NHnFSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3US2ZKSzVyPUmuOlk3PTNizszN NIDNcoJUSU6JRWK=
HUTU-80 NHT1d41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTudlFKSzVyPUmuO|Q3PDJizszN NHjOWY9USU6JRWK=
LS-411N MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjIXnQyUUN3ME2xNE4xPTZ5IN88US=> M2DwW3NCVkeHUh?=
RPMI-8402 NVvSWG5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\1dYx7UUN3ME2xNE4yOTZizszN MXPTRW5ITVJ?
KU812 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\CTWM2OD1zMD6yPVkyKM7:TR?= M{HZdHNCVkeHUh?=
EW-1 M{TVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13LOWlEPTB;MUCuOFQzPSEQvF2= NYKyOm43W0GQR1XS
HC-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LXT2lEPTB;MUCuOFg1PCEQvF2= MYPTRW5ITVJ?
NB69 Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjq[mZKSzVyPUGwMlUxPDNizszN NVnSO4JXW0GQR1XS
MFH-ino NWXPPIlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;je|YyUUN3ME2xNE45OzB|IN88US=> MkK4V2FPT0WU
CCRF-CEM MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGzTJFKSzVyPUGxMlU6PyEQvF2= NYj1UFdnW0GQR1XS
SK-N-DZ NHnPd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jIV2lEPTB;MUKuNFQ{PiEQvF2= Mn7HV2FPT0WU
NCI-H720 M2\HfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF{LkG3NFUh|ryP MYrTRW5ITVJ?
HCC1187 M{jGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni1TWM2OD1zMj6yNFQyKM7:TR?= NFHpR3RUSU6JRWK=
IST-SL2 NFjlT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrMeJNKSzVyPUGyMlQ5PzJizszN MVzTRW5ITVJ?
KE-37 NXO5WVBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi3R3VKSzVyPUGyMlc6PjZizszN MoLmV2FPT0WU
HCC1599 NYHmWnlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXkUnFKSzVyPUGyMlkxPjlizszN MXvTRW5ITVJ?
A4-Fuk MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF{Lkm1PFYh|ryP M{fLT3NCVkeHUh?=
NKM-1 M4jJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PpVmlEPTB;MUOuNlkzPSEQvF2= NGe1UZVUSU6JRWK=
BE-13 NHTETndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:wcXRRUUN3ME2xN{44QTh7IN88US=> NV\4RoRlW0GQR1XS
MV-4-11 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfyWGJCUUN3ME2xOE4xOzJ2IN88US=> MWLTRW5ITVJ?
OPM-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF2LkSwPFUh|ryP M4fVSHNCVkeHUh?=
KARPAS-422 M1P3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PEbGlEPTB;MUSuOVEzPiEQvF2= M{DudXNCVkeHUh?=
RPMI-8226 NHHMTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHqTWM2OD1zND64PVE2KM7:TR?= MV;TRW5ITVJ?
KARPAS-45 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;4elhKSzVyPUG1Mlc4OTZizszN MXTTRW5ITVJ?
SK-PN-DW NYXHO5NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrFVIJKSzVyPUG1Mlg3OzFizszN M{f2OHNCVkeHUh?=
LC-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF4LkG1NFYh|ryP MnW5V2FPT0WU
NCI-H1648 NFzofXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv4e3hUUUN3ME2xOk4zPTRizszN NEn4UXhUSU6JRWK=
RL95-2 NGXwOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF4LkO5O|gh|ryP NYOwU4lvW0GQR1XS
KNS-42 NFS1fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF4LkeyO|Qh|ryP MV3TRW5ITVJ?
RPMI-6666 Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzTc4lKSzVyPUG2MlkzOTFizszN NV;PeXFuW0GQR1XS
SIG-M5 NX3OVVRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF5LkG5NFMh|ryP NXHScVNCW0GQR1XS
VA-ES-BJ NWPLe4dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLlXItKSzVyPUG3Mlc1PTFizszN NWLqWFdvW0GQR1XS
MONO-MAC-6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\uZVNKSzVyPUG3Mlk{OTJizszN NYrzNWV2W0GQR1XS
LAN-6 NELxOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHCc2tjUUN3ME2xPE44PTV5IN88US=> M3rBenNCVkeHUh?=
A388 NF7tNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rlVWlEPTB;MUmuN|A2QSEQvF2= MkD5V2FPT0WU
SK-NEP-1 NWLqcYZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHrdJhKSzVyPUKwMlIyOzJizszN NUPsWZNCW0GQR1XS
TE-10 NVjRb3J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf5TWM2OD1{MD61NlIyKM7:TR?= NIf0WmlUSU6JRWK=
HL-60 M4L6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi5TWM2OD1{MD65NFk6KM7:TR?= NI\lXIFUSU6JRWK=
MC116 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;RNmRnUUN3ME2yNU44OjJzIN88US=> MWDTRW5ITVJ?
SW962 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJzLke5NVUh|ryP MnfUV2FPT0WU
NOMO-1 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLsb2RbUUN3ME2yNk43PTZ2IN88US=> NVrGPWJ3W0GQR1XS
CTB-1 NIHCTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETr[mxKSzVyPUKyMlg3PzFizszN MYHTRW5ITVJ?
MRK-nu-1 NXHPb29XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rW[mlEPTB;MkKuPVA4PCEQvF2= NViyR25HW0GQR1XS
GR-ST MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrxd5ZKSzVyPUKzMlc3KM7:TR?= NX;5bXVGW0GQR1XS
HH MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LEd2lEPTB;MkSuNFA{KM7:TR?= NUe1WnRiW0GQR1XS
NCI-H1963 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HZe2lEPTB;MkSuNFc5OiEQvF2= MmrkV2FPT0WU
QIMR-WIL NXzUVWRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX1TWM2OD1{ND64O|czKM7:TR?= MlrCV2FPT0WU
CGTH-W-1 MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHlTWM2OD1{NT6wO|I{KM7:TR?= NHG0eXZUSU6JRWK=
LP-1 NHrPZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[0TWM2OD1{NT62OVUyKM7:TR?= Mnm0V2FPT0WU
NCI-H748 MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJ4LkWxN|ch|ryP M2X3RnNCVkeHUh?=
PF-382 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPrVlJKSzVyPUK3MlIzOjNizszN MlP2V2FPT0WU
ATN-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPhW4VKSzVyPUK3MlM4OzJizszN MmH6V2FPT0WU
L-540 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDDPZBKSzVyPUK3MlY1PTlizszN MUXTRW5ITVJ?
LXF-289 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\DTWM2OD1{Nz63OVE6KM7:TR?= NE\xfIJUSU6JRWK=
LS-513 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDmWpc6UUN3ME2yPE4yQDB5IN88US=> MVPTRW5ITVJ?
NCI-H1581 NWHaSnhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrZS5FsUUN3ME2zNE4{QTd4IN88US=> MV3TRW5ITVJ?
ES6 NVHDPYw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX35NXNGUUN3ME2zNE43QDl7IN88US=> MljXV2FPT0WU
SW982 NVTHcHlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXUO|JKSzVyPUOwMlg2PjZizszN MUHTRW5ITVJ?
DOHH-2 M{niRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNzLkW4PVMh|ryP M4TvOnNCVkeHUh?=
DB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnVTWM2OD1|Mz65OFMyKM7:TR?= NYTSdZBjW0GQR1XS
MPP-89 NY[wV5VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\YTWM2OD1|ND6xO|U3KM7:TR?= NVTNS|lIW0GQR1XS
LB831-BLC MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTN2LkWxPFQh|ryP MXTTRW5ITVJ?
NB5 MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO3OHZKSzVyPUO0Mlg2OzVizszN NIHRdoJUSU6JRWK=
GB-1 Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDFPXVTUUN3ME2zOU4xPDZ7IN88US=> MXvTRW5ITVJ?
TE-15 NWLXOZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTN3LkKyN|gh|ryP MVLTRW5ITVJ?
LC4-1 NGTPfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHSWIZKSzVyPUO1MlM5PDdizszN NXm3Wol7W0GQR1XS
NCI-H747 NFrhTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DhbWlEPTB;M{[uNVM3QSEQvF2= M3jYZnNCVkeHUh?=
NTERA-S-cl-D1 MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf2OmZyUUN3ME2zPE44OzR5IN88US=> MWTTRW5ITVJ?
SK-MM-2 NVXqWYdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mzc2lEPTB;NECuNVE1PiEQvF2= MUfTRW5ITVJ?
TGW Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrjeJl1UUN3ME20NU4xPTZ|IN88US=> NEnG[WRUSU6JRWK=
ONS-76 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\hSYRKSzVyPUSyMlQ5QDNizszN M3HkNXNCVkeHUh?=
CPC-N M3\rbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTR{Lkm5O|Eh|ryP MX;TRW5ITVJ?
ES4 NGfzRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vtfmlEPTB;NESuOFE2OyEQvF2= MULTRW5ITVJ?
Daudi MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTR3LkC4Nlch|ryP NX;5XFZZW0GQR1XS
MOLT-4 M3nXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq4TWM2OD12NT6wPFU{KM7:TR?= M3rpO3NCVkeHUh?=
HT-144 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zvTWlEPTB;NE[uO|I3KM7:TR?= MkTvV2FPT0WU
SW872 NY\QdZFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H4SWlEPTB;NEiuNVk{OyEQvF2= NVXHVYJxW0GQR1XS
D-283MED NFOzVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LjXGlEPTB;NEiuN|U1OiEQvF2= MX3TRW5ITVJ?
NCI-H2126 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M321WGlEPTB;NEiuPFQ4PiEQvF2= M2PzTXNCVkeHUh?=
NCI-SNU-16 MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;MTHl[UUN3ME20PU4zOTR|IN88US=> M{nvPXNCVkeHUh?=
CESS NWHKWFZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\GTWM2OD12OT61NFg5KM7:TR?= MnjHV2FPT0WU
A101D Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLYTWM2OD12OT65O|M3KM7:TR?= MXrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03737994 Not yet recruiting ALK Gene Rearrangement|ALK Positive|Non-Squamous Non-Small Cell Lung Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 National Cancer Institute (NCI) January 13 2019 Phase 2
NCT03672643 Not yet recruiting ALK-positive NSCLC Pfizer December 28 2018 Phase 4
NCT03707847 Recruiting ALK-Positive Anaplastic Large Cell Lymphoma Mingzhi Zhang|Zhengzhou University October 1 2018 Phase 4
NCT03646994 Recruiting Effectiveness and Safety for Real World Study on Crizotinib Used for ROS1 Arranged Non-squamous Non-small Cell Lung Cancer Hunan Province Tumor Hospital August 1 2018 --
NCT03647111 Recruiting Non-small Cell Lung Cancer Hunan Province Tumor Hospital August 1 2018 --
NCT03620643 Not yet recruiting Lobular Breast Carcinoma|Gastric Cancer Royal Marsden NHS Foundation Trust|Pfizer|Breast Cancer Now August 13 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products4

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID